Phase 1a: First-in-Human Single Ascending Dose Study (NCT02951806) Study Title: "Safety, Tolerability, and Pharmacokinetics of Single Doses of Cagrilintide in Healthy Subjects" Status: Completed Phase: Phase 1a Enrollment: 48 healthy volunteers Study Period: 2016-2017 Location: Single center (Denmark) Design: Randomized, double-blind, placebo-controlled, single ascending dose Dose Range: 0.03-10 mg SC Primary Endpoints: Safety, tolerability, PK parameters Population: Healthy male subjects, BMI 20-28 Key Results: Pharmacokinetics: Terminal half-life 5-7 days across dose range
Turmeric has been shown to have the potential to raise glutathione levels, and it's wise to cut back on alcohol, as it can deplete your glutathione stores
But between reconstitution math, syringe markings, and weekly dose escalation, simple becomes complicated fast
doi.org/10.1038/nature05383 Chang, C
Mukhopadhya, I
But unregulated peptides may not have been studied in humans or shown to be effective or safe